
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2026

MANPOWERGROUP INC.

(Exact name of Registrant as Specified in Its Charter)

Wisconsin
(State or Other Jurisdiction
of Incorporation)

1-10686
(Commission File Number)

39-1672779
(IRS Employer
Identification No.)

**100 Manpower Place
Milwaukee, Wisconsin**
(Address of Principal Executive Offices)

53212
(Zip Code)

Registrant's Telephone Number, Including Area Code: (414) 961-1000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$.01 par value	MAN	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Election of Directors.

On October 26, 2026, ManpowerGroup Inc. (the “Company”) appointed Lidia Fonseca to its Board of Directors, with service to begin on November 1, 2026. The size of the Company’s Board of Directors will increase from twelve to thirteen directors in connection with the appointment of Ms. Fonseca. Ms. Fonseca previously served as Chief Digital and Technology Officer and Executive Vice President of Pfizer Inc. and is currently the Senior Advisor to the Chief Executive Officer of Pfizer Inc. Ms. Fonseca has not been appointed to serve on any committee of the Company’s Board of Directors.

As a non-employee director of the Company, Ms. Fonseca will participate in the same compensation arrangement as the other non-employee directors of the Company, as described in Exhibits 10.5(a) and 10.5(b) of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Under this compensation arrangement, non-employee directors receive (1) an annual cash retainer equal to \$120,000 (or, if elected by the director, deferred stock in lieu of all or a portion of the cash retainer), and (2) an annual grant of deferred stock with a grant date fair value of approximately \$180,000 (or, if elected by the director, a grant of restricted stock). Ms. Fonseca will receive a prorated retainer and annual grant in connection with her service in 2026. Ms. Fonseca will also be entitled to receive reimbursement for travel expenses incurred in connection with attending Board of Directors and, if applicable, committee meetings.

There are no family relationships between Ms. Fonseca and any director or executive officer of the Company, and no arrangements or understandings between Ms. Fonseca and any other person pursuant to which she was selected as a director. Since January 1, 2025, there have been no transactions, and there are no currently proposed transactions, to which the Company was or is a participant and in which Ms. Fonseca had or is to have a direct or indirect material interest that would require disclosure pursuant to Item 404(a) of Regulation S-K.

The Company will also enter into an indemnification agreement with Ms. Fonseca, which will be in substantially the same form as the indemnification agreements entered into by the Company with each of the Company’s other outside directors. A copy of the indemnification agreement is filed as Exhibit 99.1 to the Company’s Current Report on Form 8-K dated October 31, 2006 and is incorporated herein by reference.

The press release issued by the Company announcing the appointment of Ms. Fonseca is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Exhibits.

Exhibit No.	Description
-------------	-------------

99.1	Press Release dated October 28, 2026
------	--

104	Cover Page Interactive Data File (embedded within the Inline XBRL document)
-----	---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MANPOWERGROUP INC.

Date: October 28, 2026

By: /s/ Dale Johnson
Name: Dale Johnson
Title: Corporate Secretary and Chief Ethics & Compliance Officer

MEDIA CONTACT:

John Julitz

+1 (414) 502-9314

john.julitz@manpowergroup.com

ManpowerGroup Elects Lidia Fonseca to its Board of Directors

MILWAUKEE, WI (October 28, 2026) — ManpowerGroup (NYSE: MAN) today announced the election of Lidia Fonseca, former Executive Vice President and Chief Digital and Technology Officer at Pfizer, to its Board of Directors, effective November 1, 2026.

"Lidia brings a rare combination of technology leadership, business transformation experience and a clear understanding of how AI can create value at scale," said Jonas Prising, ManpowerGroup Chair & CEO. "Her strategic perspective, operational expertise and track record of leading change strengthen our ability to evolve the business and advance our transformation strategy. We are pleased to welcome her to our Board."



Fonseca served as Chief Digital and Technology Officer and Executive Vice President of Pfizer from January 2019 to April 2026, leading the company's enterprise AI, digital, data and technology strategy, as well as Learning & Development, and Business Process Excellence. She built Pfizer's enterprise AI program from inception, and scaled it across the enterprise, contributing to significant growth and cost savings. She currently serves as Senior Advisor to Pfizer's Chief Executive Officer and serves on the Board of Directors of Medtronic plc (NYSE: MDT).

Previously, Fonseca spent a decade in diagnostics as Senior Vice President and Chief Information Officer of

Quest Diagnostics and, earlier, of LabCorp. She began her career in operations and executive leadership roles at Philips Healthcare. Fonseca holds a bachelor's degree from the University of California, Berkeley, and an MBA and a Master of Business Informatics from Rotterdam School of Management at Erasmus University.

###

ABOUT MANPOWERGROUP

ManpowerGroup® (NYSE: MAN), the leading global workforce solutions company, helps organizations transform in a fast-changing world of work by sourcing, assessing, developing, and managing the talent that enables them to win. We develop innovative solutions for hundreds of thousands of organizations every year, providing them with skilled talent while finding meaningful, sustainable employment for millions of people across a wide range of industries and skills. Our expert family of brands – Manpower, Experis, and Talent Solutions – creates substantially more value for candidates and clients across more than 70 countries and territories and has done so for more than 75 years. We are recognized consistently as a best place to work for Women, Inclusion, Equality, and Disability, and in 2026 ManpowerGroup was named one of the World's Most Ethical Companies for the 17th time; all confirming our position as the brand of choice for in-demand talent.

For more information, visit www.manpowergroup.com, or follow us on LinkedIn, Facebook, and Bluesky.

